Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.56 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728609 | 1.00 | BACE1 (0.56) | BACE1CXCL12KDRKDM4EHSD17B10 | |
| SCHEMBL15647863 | 0.88 | KDM4E (0.61) | KDM4EHSD17B10ALDH1A1HPGDALOX15 | |
| SCHEMBL15647861 | 0.88 | KDM4E (0.61) | KDM4EHSD17B10ALDH1A1HPGDALOX15 | |
| SCHEMBL31588999 | 0.84 | KDM4E (0.47) | BACE1CXCL12KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL15646509 | 0.84 | CXCL12 (0.48) | BACE1CXCL12KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL15646507 | 0.84 | CXCL12 (0.48) | BACE1CXCL12KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13489637 | 0.83 | CYP1A1 (0.48) | BACE1NFE2L2CYP1A2HSD11B1CA12 | |
| SCHEMBL31308838 | 0.83 | CYP1A1 (0.48) | BACE1NFE2L2CYP1A2HSD11B1CA12 | |
| SCHEMBL22391534 | 0.79 | APP (0.69) | BACE1CXCL12KDRKDM4EHSD17B10 | |
| SCHEMBL1536425 | 0.79 | KDM4E (0.73) | BACE1CXCL12KDRKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914613-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9580463-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2964664-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2964664-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-31 | — | — | US | disclosed |
| WO-2015102929-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-09 | — | — | WO | disclosed |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8957203-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014137869-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014070964-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014062196-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-2705049-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | BACE1 4150/4885CXCL12 3178/4885KDR 4647/4885 |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | BACE1 4150/4885CXCL12 3178/4885KDR 4647/4885 |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | BACE1 4150/4885CXCL12 3178/4885KDR 4647/4885 |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, STS | BACE1 3676/4885CXCL12 3781/4885KDR 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.